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from an average of 7.8 to 16.4 DDD/capita between 1999 and 2008. Three groups of
countries were identified: high, medium and low use of antidepressants countries.
Overall, antidepressant growth was observed (41% to 325% range) and was more
pronounced in low-use countries. By 2008, SSRIs were the predominant class in all
countries; followed by SNRIs whereas TCAs consumption went down. Over the
studied period, GDP and HE growth were aligned across countries; PE growth was
associated with antidepressant expenditures. CONCLUSIONS: Countries with
lower GDP / capita (and higher GDP growth) and lower baseline antidepressant
volumes are heading in the same direction as the higher income countries did in
the past, recording a 200-300% volume growth between 1999 and 2008). This offers
a unique opportunity tomonitor the anticipated health outcomes of their prescrip-
tion, which were missed in the past and which are valuable for future mental
health policy.
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OBJECTIVES: Sleep deprivation and disturbances can result in lowered productiv-
ity and increased errors/accidents. Existing research has documented higher use of
sleepmediations amongwomen; however, little is known about other factors such
as race, ethnicity and its association with the use of sleepmedications in a nation-
ally representative study sample. The objective of this study was to investigate the
relationship of various factors such as race, ethnicity, gender, employment status
with the use of sleepmedications in the US population.METHODS:A retrospective,
cross-sectional study design was used. Data from the 2009 Medical Expenditure
Panel Survey, a nationally representative survey of US population, were used for
this analysis. The study population included all survey respondents over the age of
18. A multiple logistic regression model was built to analyze odds of reporting use
of prescription or non prescription sleep medication. RESULTS: Of the total 20568
survey respondents, 8.28% (n 1703) used some type of medication to fall asleep in
the year 2009. The odds of reporting use of sleep medication were significantly
higher among females (OR1.404 CI 1.254-1.571) compared to males. The odds of
sleepmedication use were significantly lower among African American (OR 0.529
CI 0.453-0.617), Asian American (OR 0.387 CI 0.283-0.530) and Hispanic (OR 0.717
CI 0.621- 0.828) women compared to Non Hispanic Caucasian women. Unemploy-
ment (OR1.909 CI 1.674-2.178) and depression (OR5.009 CI 4.446-5.643) were
highly correlated with use of sleep medications. Additionally, compared to lower
income levels, higher income levels had lower odds of sleep medication use.
CONCLUSIONS: Unemployed Non-Hispanic Caucasian women in low income
households are more likely to use prescription or non prescription sleep medica-
tions. Further research on why such differences exist is necessary. The factors
identified in this study should be further investigated to identify vulnerable popu-
lations to investigate underlying causes of sleep disorders.
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OBJECTIVES: To evaluate daily average consumption (DACON) and average daily
costs (ADC) of duloxetine for patients with various pain and mood conditions sub-
sequent to the recent FDA approval of duloxetine in the management of chronic
musculoskeletal pain.METHODS: Retrospective analysis of commercially insured
patients prescribed duloxetine between January 1, 2011 and September 30, 2011
using the IMS Longitudinal Prescription and Medical Claims Database. This analy-
sis focused on patients diagnosed with only one of the following: chronic lower
back pain (CLBP), osteoarthritis (OA), fibromyalgia (FM), diabetic peripheral neuro-
pathic pain (DPNP), major depressive disorder (MDD), and generalized anxiety dis-
order (GAD). Patients were assigned to study cohorts based on ICD-9 codes re-
corded within -180/07 days of the date of the first duloxetine prescription filled
during the study interval. DACONs were defined as weighted averages of the total
number of pills dispensed by total days of supply across pill strength for all patients
within each cohort. DACONs were converted to ADCs using January 2011 average
wholesale prices (AWP). A second analysis based on prescriptions between January
1, 2010 and September 30, 2010 was conducted for comparative purposes.
RESULTS: A total of 553,253 duloxetine patients were included in the analysis.
DACONswere 1.27 (for CLBP, 1.26 for OA, 1.28 for FM, and 1.27 for DPNP, versus 1.44
for MDD (p0.0001 for each of the four pain conditions) and 1.32 for GAD. The
resultingADCs for the four pain conditions varied only slightly, from$6.99 for OA to
$7.13 for FM. ADC for MDD was notably higher ($8.00). The overall DACON for 2011
represented amodest decline from 2010,most notably for CLBP and FM (to 1.35 and
1.33, respectively; p0.0001 for both). CONCLUSIONS: 2011 DACONs and ADCs
varied little across the four chronic pain conditions for which duloxetine has been
approved for use by the FDA, all of which were significantly lower than for MDD.
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OBJECTIVES: To determine the association between depression treatment and
short-term health care expenditures using a nationally representative sample of
Medicare beneficiaries with chronic physical illnesses and depression.METHODS:
We employed a longitudinal design and used data from 2000 through 2005 of the
Medicare Current Beneficiary Survey, a nationally representative survey of Medi-
care benefi ciaries. Two years of observation, yielding five cohorts were used to
measure depression treatment in the baseline year andhealth care expenditures in
the second. The bivariate relationship between depression treatment in baseline
year and health care expenditures in the follow-up year was tested with t-tests.
Ordinary least squares (OLS) regressions on logged dollars were used to assess the
relationship between depression treatment and health care expenditures after
controlling for demographic, socio-economic, health status, and lifestyle risk
factors. RESULTS: Compared to no depression treatment ($16,795), the average
total expenditures were higher for those who used antidepressants only ($17,425)
and those who used psychotherapy with or without antidepressants ($19,733).
After controlling for the independent variables, antidepressant use and psycho-
therapy with or without antidepressants were associated with 21% and 31% in-
crease in total expenditures, respectively. For each expenditure type except for the
other category, we observed a statistically significant relationship between depres-
sion treatment and expenditures. CONCLUSIONS: Among the elderly with chronic
physical illnesses, depression treatment was associated with greater short-term
health care expenditures. Future research needs to examine whether this relation-
ship remains over a longer period of time.
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OBJECTIVES: The purpose of this studywas to compare adherence and persistence
for patients treated with duloxetine across several diagnoses categories: major
depressive disorder (MDD), fibromyalgia (FM), osteoarthritis (OA), and chronic
lower back pain (CLBP). METHODS: Patients age 18-64 initiating duloxetine treat-
ment during 2008 were identified in the Thomson Reuters MarketScan® Database.
The index event was defined as the first duloxetine prescription filled during the
study period with no duloxetine coverage during the previous 90 days. Patients
were assigned to disease-category cohorts on the basis of ICD-9 codes recorded on
medical claims dated within 1/- 3 month of the initial duloxetine prescription.
Adherence was measured over both 365- and 90-day post duloxetine initiation
periods as the percent of patients with a medication possession ratio 0.8. Persis-
tencewasmeasured over a 365-day post-initiation period as the percent of patients
with length of therapy  180 days. 2-tests were used to compare differences in
adherence and persistence across patient cohort. RESULTS: A total of 18,406 pa-
tients with one of the 4 identified diagnosis categories were identified as initiating
duloxetine in 2008: MDD (8,334), FM (3,630), OA (1,458) or CLBP (4,984). Adherence
was directionally greater among patientswithMDD (37.3%) versus FM (35.3%) or OA
(35.7%), and statistically significantly greater than CLBP (29.9%; p0.005). Compar-
isons of 90-day adherences were similar, with MDD (58.8%) directionally higher
than FM (54.1%) or OA (57.8%), and statistically significantly greater than CLBP
(50.0%; p0.005). Comparisons of persistencewere similar to adherence. For exam-
ple, persistence was 47.5% for MDD versus 38.7% for CLBP (p0.005).
CONCLUSIONS: Duloxetine adherence and persistence were similar among pa-
tients with MDD, FM, and OA, and significantly less among those with CLBP. These
relationships were consistent across variations in technical assumptions em-
ployed in calculating the study measures.
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OBJECTIVES: The study examined antidepressant utilization patterns and expen-
ditures in older adults in United States (US). METHODS: The study involved anal-
ysis of household and prescription files of the 2009 Medical Expenditure Panel
Survey (MEPS) data. The study sample included all older adults ( 50 years) with
depression. The analysis focused on antidepressant classes, namely selective se-
rotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAO),
phenylpiperazine and tetracyclics. Descriptive weighted analysis was performed
to examine antidepressant use patterns and prescription expenditures in commu-
nity dwelling depressed older adults. RESULTS: According to the 2009 MEPS, 11.36
million older adults were diagnosed with depression for an overall prevalence of
11.50% (95% CI, 12.34- 47.50). Most older adults with depression were 50-64 years of
age (66.79%), female (67.25%), and white (89.85%). Antidepressants were used by
78.61% (95% CI, 75.79- 81.43) of older adults with depression. The most prescribed
class of antidepressants was SSRIs (54.86%), followed by SNRIs (18.49%), phe-
nylpiperazine (7.92%), TCAs (6.96%) and tetracyclics (3.19%). Total antidepressant
prescriptionexpenditureswere $9.5 billion (95%CI, 8.3-10.7 billion).Highexpenditures
were found for SNRI ($4.3 billion, or 44.62% of antidepressant expenditures), followed
by SSRI ($3.5 billion, or 37.60%)), TCA ($172 million, or 1.8%), and phenylpiperazine
($131 million, or 1.37%). The average prescription price was also highest for SNRI
($181.56), followed by SSRI ($49.22), tetracyclic ($28.17), TCA ($19.13), and phe-
nylpiperazine ($13.64). CONCLUSIONS: Depression is highly prevalent among older
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adults. Over three-fourths of older adults with depression use antidepressants for
annual expenditure of nearly $10 billion, mostly for SNRIs and SSRIs.
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OBJECTIVES: Polypharmacy has now become a norm instead of an exception in the
treatment of pediatric bipolar disorder (PBD). The objective of the study was to
identify the most commonly used psychotropic combinations in PBD patients and
to evaluate the se ’ adherence patterns of the combination regimens. METHODS:
2003-2007 Medicaid Analytic eXtract (MAX) data files from 4 US states were used.
Children and adolescents (6-18 years)were identified if theywere newly discharged
fromahospitalwith bipolar disorder as their primary diagnosis. Polypharmacywas
operationally defined as at least 14 days overlap between the episodes of 2 psycho-
tropic drugs. These patients were followed for a year since their hospital discharge
to observe the adherence patterns. Adherence for combination regimenswasmea-
sured usingmedication possession ratio (MPR), calculated for each individual drug
separately and compared with the adherence when the drug was used alone. Mul-
tivariate logistic regression analysis was performed to examine the factors associ-
ated with treatment adherence. RESULTS: Of the 7337 PBD patients identified,
about 70% (n5142) received combination treatments, and 62% (n4540) received
combinations of an atypical antipsychotic plus a mood stabilizer. Overall MPRs for
monotherapy and polypharmacy users were 0.69(0.26) and 0.74(.024), respec-
tively. Multivariate analysis revealed that the combination users had higher MPRs
as compared to the correspondentmonotherapy users.When compared to atypical
antipsychotic monotherapy users, combination users who initiated with an atyp-
ical monotherapy (OR1.3;CI1.12-1.5), atypical plus mood stabilizer(OR1.27;
CI1.1-1.47) and two atypicals (OR2.45;CI1.26-4.74) were all associatedwith bet-
ter compliance. Other factors associated with higher MPRs were being white
(O.R1.71;C.I.1.48-1.98) and foster care (O.R.2.19;C.I.1.91-2.51). Older age group
(13-18 years) (O.R0.81;C.I.0.71-0.92), however, was associated with having lower
MPRs. CONCLUSIONS: Psychotropic polypharmacy is common among children and
adolescents with bipolar disorder. Addition of another psychotropic medication to
monotherapy regimen often leads to improvement in medication adherence.
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OBJECTIVES: Studies have indicated that approximately 80 to 95 percent of gaba-
pentin use is off-label. However, evidence in support of these off label uses is
limited. There is an increasing body of research on the efficacy of gabapentin for
treating pain and mental conditions, but much of this work (especially that for
mental conditions) is preliminary and suggestive at best. The objective of this study
is to examine, using a nationally representative sample, the efficacy of gabapentin
in treating the wide range of off-label conditions for which there is little or no
evidence and the few conditions for which there is already some evidence.
METHODS: The study uses the 1997-2007 Medical Expenditure Panel Data set. Us-
ers of gabapentin were identified and the top 20 ICD9 Codes, by age group, associ-
ated with prescriptions for gabapentin were used to select control subjects. Sub-
samples associated with pain, neurologic conditions, mental health, and other
off-label conditions were created. Ordinary least squares and propensity score
matching following the regression method attributed to Hirano and Imbens were
used to examine the association of gabapentin and self-reported health (physical
and mental health) with controls for lagged health, age, gender, race, income,
education, insurance, and co-morbidities. RESULTS: Use of gabapentin was nega-
tively associated with reporting of good physical or mental health in almost all
cases. The coefficients in the propensity score controlled models tended to be
smaller but still suggested a significant relationship between gabapentin use and a
5-10% lower probability of reporting good physical or mental health.
CONCLUSIONS: There was little evidence that the use of gabapentin is associated
with better self-reported physical or mental health and lower medical spending.
There is a strong case for improved efforts to promote evidence based use of med-
ications as there is a potential for significant expenditures with little or no impact
on health.
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OBJECTIVES: Antidepressant prescribing have changed globally over the last few
years, with conventional drugs like tricyclics and MAO inhibitors being gradually
replaced by selective serotonin reuptake inhibitors (SSRIS) and novel antidepres-
sants. The prescribing of antidepressants varies by country, and the type of anti-
depressant chosen is influenced by both physician and patients. The aim of this
study was to assess prescribing and usage pattern of antidepressant medications
and cost of them.METHODS: A retrospective cross-sectional study was carried out
on insurance prescriptions during 3 years from2007 to 2009. All insurance prescrip-
tions were collected using especial software called Rx Analyst during the study
period in the National Committee of Rational Drug Use, and then reviewed for
prescriptions included at least one dosage form of antidepressants. Data related to
dispensing of antidepressants were obtained from the official databank of national
regulatory authority. Drugs were classified according to the Anatomic Therapeutic
Chemical (ATC-1999 edition) System. RESULTS: A total of more than 224 million
prescriptions were reviewed. The number of antidepressants that prescribed were
134 million (4.18%), 155 million (4.34%) and 173 million (4.17%) in 2007, 2008, and
2009, respectively. Meanwhile, the number which dispensed from wholesaler to
retail pharmacies in that period was 945 million (3.23%), 960 million (3.33%), and 1
billion (3.35%) in 2007, 2008, and 2009, respectively. Themost frequently prescribed
substances were nortriptylline, fluoxetine, and citalopram, which accounted for
67% of all prescriptions. The total price of antidepressant prescribed during study
period was 15264270 US$ and total sale was 111442111 US$ obtained from national
sale data. CONCLUSIONS: There is a remarkable variation in antidepressants pre-
scribing and dispensing that might be related to self-medication of these com-
pounds. A multi interventional policy including educational, regulatory, manage-
rial, and financial strategies for professions andpublic should be planed to promote
rational use of antidepressant medications.
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Sedative hypnotic drugs are widely used to treat sleep disorders, but it is unclear
how their utilization varies by drug and patient diagnosis. OBJECTIVES: TO DE-
SCRIBE UTILIZATION PATTERNS FOR VARIOUS SEDATIVE HYPNOTIC DRUGS IN
PATIENTS WITH AND WITHOUT A CLAIM FOR INSOMNIA. METHODS: This study
was a cohort analysis of sedative hypnotic utilization in the US-based Marketscan
commercial health care claims database for 2008-2010. Patients included those
with and without an ICD-9 code for insomnia who were treated with sedative
hypnotics including zolpidem, zaleplon, eszopiclone, and selected benzodiaz-
epines (alprazolam, lorazepam, and diazepam). Outcomes includedmean andme-
dian number of prescriptions filled, duration between refills, and switching pat-
terns over 1 year of follow-up. RESULTS: A substantial proportion of sedative
hypnotic use (55-92%, depending on the drug) is in patients without an insomnia
diagnosis. Themeannumber of prescriptionswas consistently higher in thosewith
than without an insomnia diagnosis. In zolpidem, those with an insomnia diagno-
sis received amean of 4.8 (95% CI 4.76-4.81) prescriptionswithin a year, while those
without an insomnia claim received 2.8 (95%CI 2.82-2.84). Similarly, the duration of
time between refills was lower for those with than without an insomnia claim; for
zolpidem, themean number of days between refills was 63.3 and 83.6, respectively.
The duration between prescriptions also varied by drug, with zolpidem and eszo-
piclone having a shorter mean number of days between refills than zaleplon or the
benzodiazepines (75, 65, 84 or 90, respectively). More patients with than without
insomnia claims (26.7% vs. 9.4%) switched from one sedative hypnotic drug to
another. CONCLUSIONS:Drug utilization in users of sedative hypnotics varies sub-
stantially by diagnosis and drug. Those with claims for insomnia receive drug for
longer periods of time, and with less time between refills than those without doc-
umented insomnia diagnoses.
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OBJECTIVES: In April 2005, the Food and Drug Administration (FDA) issued a black
box warning (BBW) regarding the risks of using atypical antipsychotics (AAPs) for
behavioral disorders in elderly patientswith dementia. The objective of the present
studywas to investigate the impact of the BBWon the utilization of AAPs in elderly
non-institutionalized dementia population.METHODS:Medical Expenditure Panel
Surveys, from year 2004 through 2007, were used in the study. Utilization rates of
AAPs pre-warning (2004-2005) and post-warning (2006-2007) weremeasures of pri-
mary interest in both overall and Medicare samples. Chi-square tests and multi-
variate logistic regression analyses were performed to examine pre-post differ-
ences in utilization rates (defined as elderly patients taking at least onemedication
associated with dementia) and gain insights into patterns of AAP use with respect
to demographic, insurance and other factors. RESULTS: AAP use declined in the
post-warning period for the main sample (X2 0.81, p0.3668) as well as Medicare
sample (X2 2.72, p0.0992). However the decline was not statistically significant.
Additionally, bivariate analyses of the main sample showed significantly higher
proportion of patients receiving AAPs in the post-warning period for individuals
with prescription drug coverage (x2 21.63, p 0.0001). In contrast, a similar anal-
ysis for the Medicare sample revealed significantly higher proportion of patients
receiving AAPs in the post-warning period for people with no Medicare drug cov-
erage (x2 20.83, p 0.0001). Further, logistic regression analyses showed no sig-
nificant decline in the use of AAPs in the post-warning period for the main sample
(Odds Ratio, OR  0.831, CI  0.366 – 1.885) as well as the Medicare sample (OR
0.798, CI 0.364 – 1.753). CONCLUSIONS: The regulatory warnings and labeling
changes regarding off-label use of AAPs in dementia treatment seem to havemade
little impact on the actual use in non-institutionalized populations.
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